Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

BACKGROUND: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung cancer. We aimed to assess the safety and activity of rov...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Autores principales: Rudin, Charles M, Pietanza, M Catherine, Bauer, Todd M, Ready, Neal, Morgensztern, Daniel, Glisson, Bonnie S, Byers, Lauren A, Johnson, Melissa L, Burris, Howard A, Robert, Francisco, Han, Tae H, Bheddah, Sheila, Theiss, Noah, Watson, Sky, Mathur, Deepan, Vennapusa, Bharathi, Zayed, Hany, Lally, Satwant, Strickland, Donald K, Govindan, Ramaswamy, Dylla, Scott J, Peng, Stanford L, Spigel, David R
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5481162/
https://ncbi.nlm.nih.gov/pubmed/27932068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30565-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares